AnaptysBio, Inc. (ANAB)

AnaptysBio Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	234.6	91.28	17.16	10.29	63.18
Revenue Growth (YoY)	157.01%	432.03%	66.78%	-83.72%	-15.77%
Gross Profit	234.6	91.28	17.16	10.29	63.18
Selling, General & Admin	50.74	42.39	41.95	36.64	21.49
Research & Development	135.97	163.84	132.28	88.8	98.5
Other Operating Expenses	-	-	7.34	-	-
Total Operating Expenses	186.71	206.23	181.57	125.44	119.99
Operating Income	47.9	-114.95	-164.41	-115.15	-56.81
Interest Income	13.5	19.79	18.87	7.55	0.43
Interest Expense	-79.89	-50.09	-18.08	-21.11	-1.45
Other Non-Operating Income (Expense)	-55.53	-30.27	0.79	-13.53	-0.95
Total Non-Operating Income (Expense)	-121.93	-60.56	1.58	-27.09	-1.96
Pretax Income	-13.07	-145.23	-163.62	-128.7	-57.8
Provision for Income Taxes	-0.16	-0	0	-0.02	-
Net Income	-13.23	-145.23	-163.62	-128.72	-57.8
Net Income to Common	-13.23	-145.23	-163.62	-128.72	-57.8
Shares Outstanding (Basic)	29	28	27	28	27
Shares Outstanding (Diluted)	29	28	27	28	27
Shares Change (YoY)	1.32%	5.42%	-4.41%	2.68%	0.47%
EPS (Basic)	-0.46	-5.12	-6.08	-4.57	-2.11
EPS (Diluted)	-0.46	-5.12	-6.08	-4.57	-2.11
Free Cash Flow	19.61	-135.7	-121.61	-73.95	-47.29
Free Cash Flow Per Share	0.68	-4.78	-4.52	-2.63	-1.72
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	20.42%	-125.93%	-958.27%	-1119.41%	-89.93%
Profit Margin	-5.64%	-159.10%	-953.66%	-1251.33%	-91.49%
FCF Margin	8.36%	-148.66%	-708.79%	-718.88%	-74.85%
EBITDA	48.46	-114.34	-163.76	-114.48	-56.2
EBITDA Margin	20.65%	-125.27%	-954.47%	-1112.85%	-88.95%
EBIT	47.9	-114.95	-164.41	-115.15	-56.81
EBIT Margin	20.42%	-125.93%	-958.27%	-1119.41%	-89.93%
Effective Tax Rate	1.25%	0.00%	-0.00%	0.02%	0.00%

Updated Mar 3, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q